Outcomes for Dostarlimab and Real-World Treatments in Post-platinum Patients With Advanced/Recurrent Endometrial Cancer: The GARNET Trial Versus a US Electronic Health Record-Based External Control Arm

Outcomes for Dostarlimab and Real-World Treatments in Post-platinum Patients With Advanced/Recurrent Endometrial Cancer: The GARNET Trial Versus a US Electronic Health Record-Based External Control Arm

# Background Patients with advanced or recurrent endometrial cancer (EC) have limited treatment options following platinum-based chemotherapy and poor prognosis. The single-arm, Phase I GARNET trial (NCT02715284) previously reported dostarlimab efficacy in mismatch repair–deficient/microsatellite in...

Full description

Saved in:
Bibliographic Details
Main Authors: Scott Goulden, Qin Shen, Robert L. Coleman, Cara Mathews, Matthias Hunger, Ankit Pahwa, Rene Schade
Format: Article
Language:English
Published: Columbia Data Analytics, LLC 2023-09-01
Series:Journal of Health Economics and Outcomes Research
Online Access:https://doi.org/10.36469/001c.77484
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items

Similar Items